argenx gains on fresh immunology data and upbeat analyst commentary

argenx SE (ARGX) is up 4.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to investor optimism around new long-term data for efgartigimod presented around a major European rheumatology meeting, reinforcing the drug’s durability and safety profile in additional autoimmune indications beyond its current commercial base. The stock may also be getting a lift from supportive sell-side commentary reiterating a bullish rating and high price target.

Details:

New interim long-term results from the ALKIVIA+ open-label extension in autoimmune myositis showed sustained functional improvement through week 52, with a safety profile described as consistent over longer exposure.

Data from the RHO+ open-label extension in Sjogren’s disease highlighted maintenance of response on clinical measures for patients continuing treatment and improvements for those switching from placebo, with no new safety signals noted in long-term use.

A cross-indication safety analysis spanning multiple clinical studies cited a consistent tolerability profile across 834 treated patients and more than 1,300 patient-years of follow-up.

argenx also scheduled a June 23, 2026 myositis-focused R&D webinar, which can keep attention on the ALKIVIA program and upcoming pipeline milestones.

Sources:

argenx SE (press releases), GlobeNewswire, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ARGX Hedge Fund Activity

We have seen 235 institutional investors add shares of $ARGX stock to their portfolio, and 296 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

M&T BANK CORP added 774,916 shares (+20977.7%) to their portfolio in Q4 2025, for an estimated $651,665,610
FMR LLC removed 601,285 shares (-10.8%) from their portfolio in Q1 2026, for an estimated $439,088,371
WELLINGTON MANAGEMENT GROUP LLP added 342,221 shares (+50.4%) to their portfolio in Q1 2026, for an estimated $249,906,885
SANDS CAPITAL MANAGEMENT, LLC added 340,245 shares (+2046.6%) to their portfolio in Q4 2025, for an estimated $286,129,032
CAPITAL WORLD INVESTORS added 339,982 shares (+17.7%) to their portfolio in Q1 2026, for an estimated $248,271,855
INVESCO LTD. added 331,489 shares (+390.4%) to their portfolio in Q4 2025, for an estimated $278,765,674
ARTISAN PARTNERS LIMITED PARTNERSHIP removed 288,960 shares (-16.4%) from their portfolio in Q1 2026, for an estimated $211,013,040

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ARGX Analyst Ratings

Wall Street analysts have issued reports on $ARGX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Wedbush issued a "Outperform" rating on 01/14/2026
Truist Securities issued a "Buy" rating on 01/08/2026
Citigroup issued a "Buy" rating on 01/08/2026
Wells Fargo issued a "Overweight" rating on 12/16/2025
Stifel issued a "Buy" rating on 12/11/2025

To track analyst ratings and price targets for $ARGX, check out Quiver Quantitative's $ARGX forecast page.

$ARGX Price Targets

Multiple analysts have issued price targets for $ARGX recently. We have seen 13 analysts offer price targets for $ARGX in the last 6 months, with a median target of $1030.0.

Here are some recent targets:

David Nierengarten from Wedbush set a target price of $1000.0 on 06/04/2026
Derek Archila from Wells Fargo set a target price of $1291.0 on 06/01/2026
Gavin Clark-Gartner from Evercore ISI Group set a target price of $1059.0 on 05/15/2026
Yatin Suneja from Guggenheim set a target price of $1135.0 on 05/08/2026
Leland Gershell from Oppenheimer set a target price of $1014.0 on 04/02/2026
Colleen Kusy from Baird set a target price of $867.0 on 02/27/2026
Luca Issi from RBC Capital set a target price of $890.0 on 02/27/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.